Aptus Pharma reported standalone FY26 revenue of ₹46.71 crore, up 89.59% YoY, with EBITDA at ₹7.50 crore.
The company expanded its product portfolio to 250+ formulations across chronic, acute, and wellness segments.
Aptus operates through Rx, OTC, Global, and ORBIT verticals with distribution covering 25,000+ retail outlets.
Board approved financial results for year ended March 31, 2026, filed pursuant to SEBI Listing Regulations.